NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces financial results for the third quarter ended September 30, 2025, and provides a corporate update. Jeffrey Meckler, Indaptus Therapeutics’ Chief Executive Officer, commented, “We have completed the Safety Lead-In cohort, dosing six evaluable participants with the c ...

Core Insights - Earnings season presents opportunities for lesser-known companies to gain attention, with three stocks highlighted for potential comebacks if their earnings reports are favorable [2] Company Overview - Scholar Rock Holding Corp. (NASDAQ: SRRK) is a biotech firm focused on developing protein therapeutics for neuromuscular diseases [3] - The lead asset, apitegromab, targets Type 2 and Type 3 Spinal Muscular Atrophy (SMA) and has shown promising Phase 3 data, indicating strong potential for regulatory approval in 2026 [4] Financial Performance - Scholar Rock's shares have declined approximately 33% year-to-date due to manufacturing site issues, raising short-term concerns [4] - The company is projected to report a loss per share of 76 cents for the third quarter, with no revenue expected yet [6] Clinical Development - A Phase 2 study of apitegromab demonstrated over 54% lean mass preservation compared to control when combined with GLP-1 agonist tirzepatide, indicating the drug's therapeutic promise [5] - Investors should look for updates on apitegromab and other drugs in the pipeline during the upcoming earnings report [6] Market Sentiment - Quarterly earnings reports can significantly impact share prices, with Scholar Rock, along with Globant and NiCE, being identified as companies that may see a rebound if they deliver strong earnings [7]

MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity, will deliver a corporate update at the Bell Potter Healthcare Conference, a virtual event showcasing Australia’s best healthcare companies. Presentation details AUSTRALIA ...

32 patients with autoimmune disease treated with AlloNK plus anti-CD20 monoclonal antibody (mAb) as of October 1, 2025, data cutoff All patients received AlloNK as outpatients, and the majority were treated in community rheumatology trial sites with no specialized oncology oversight, demonstrating the feasibility of administering this regimen outside the hospital setting No cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) Consistent and complete B-cell deple ...

Core Insights - ProMIS Neurosciences Inc. is advancing its lead candidate PMN310 for Alzheimer's disease, with over 85% enrollment in the Phase 1b PRECISE-AD trial and a favorable safety profile reported [1][6][8] - The company has successfully raised capital to support its strategic goals and has strengthened its board with the addition of a new member [2] - Financial results for Q3 2025 show an increase in cash reserves and a significant rise in research and development expenses due to the ongoing clinical trial [5][11] Alzheimer's Disease Program (PMN310) - PMN310 is a humanized IgG1 antibody targeting toxic AβO, which are believed to drive Alzheimer's disease [3][8] - The drug has received Fast Track Designation from the U.S. FDA, indicating its potential to address unmet medical needs in AD [3][8] - The ongoing PRECISE-AD trial is designed to evaluate the safety, tolerability, and pharmacokinetics of PMN310, with interim data expected in Q2 2026 and final results in Q4 2026 [1][9] Financial Highlights - As of September 30, 2025, ProMIS reported cash and cash equivalents of $15.4 million, up from $13.3 million at the end of 2024, primarily due to capital-raising activities [5] - Research and development expenses for Q3 2025 were $9.8 million, a significant increase from $2.6 million in the same period of 2024, reflecting the costs associated with the PRECISE-AD trial [11] - The company reported a loss from operations of $11.8 million for Q3 2025, compared to a loss of $4.4 million in Q3 2024, driven by increased trial expenditures [11][17] Key Pipeline Programs - PMN267, targeting toxic misfolded TDP-43 for amyotrophic lateral sclerosis (ALS), is ready to progress to IND-enabling studies [6] - PMN442, aimed at Parkinson's disease and multiple system atrophy, is also prepared to move forward to IND-enabling studies [6] Company Overview - ProMIS Neurosciences is focused on developing therapeutic antibodies for neurodegenerative diseases, utilizing its proprietary EpiSelect™ platform to identify disease-specific epitopes [7][10] - The company is headquartered in Cambridge, Massachusetts, and Toronto, Ontario, and is committed to addressing the challenges posed by misfolded proteins in various neurodegenerative conditions [7]

Core Insights - Humacyte, Inc. reported total revenues of $753,000 for Q3 2025 and $1,571,000 for the first nine months of 2025, primarily from sales and collaborative research agreements [1][8] - The company is advancing its pipeline with plans for a Biologics License Application (BLA) filing for its acellular tissue engineered vessel (ATEV) in dialysis and initiating first-in-human studies for coronary artery bypass grafting (CABG) [1][3] - Significant sales growth of the Symvess product was noted, with Q3 sales reaching $703,000, a substantial increase from $100,000 in Q2 2025 [3][4] Financial Performance - Revenue for Q3 2025 was $753,000, with $703,000 from U.S. sales of Symvess and $50,000 from a research collaboration [8][19] - The net loss for Q3 2025 was $17.5 million, a decrease from a net loss of $39.2 million in Q3 2024 [13][19] - Research and development expenses decreased to $17.3 million in Q3 2025 from $22.9 million in Q3 2024, attributed to capitalizing costs related to Symvess manufacturing [13][19] Product Development and Pipeline - The company has received 25 Value Analysis Committee (VAC) approvals for Symvess, up from 13 in August 2025, allowing 92 civilian hospitals to purchase the product [4][5] - Positive results from the V007 Phase 3 trial for ATEV in dialysis were presented at Kidney Week 2025, indicating superior duration of use compared to autogenous fistulas [9] - Humacyte plans to submit a supplemental BLA for ATEV in dialysis in the second half of 2026, based on data from ongoing clinical trials [9][19] Intellectual Property and Research - Humacyte expanded its intellectual property portfolio with a new U.S. patent for a bioengineered esophagus, enhancing its existing claims for engineered trachea and urinary conduits [9][19] - The company published multiple studies highlighting the efficacy of Symvess in treating vascular complications, demonstrating high patency rates and limb salvage [4][5]

Core Viewpoint - MeiraGTx Holdings PLC is preparing to release its quarterly earnings, with expectations of negative earnings per share and lower revenues, which may affect investor sentiment [1][2]. Financial Performance - The anticipated earnings per share (EPS) for MGTX is -$0.50, with projected revenue around $6.9 million [2][6]. - The company has a negative P/E ratio of -4.55, indicating negative earnings, and a high price-to-sales ratio of 18.88, suggesting high market expectations for future growth [3][6]. - The enterprise value to sales ratio is 20.15, and the enterprise value to operating cash flow ratio is -5.92, reflecting negative operating cash flow [4]. - The earnings yield is -21.96%, further emphasizing the company's financial difficulties [4]. Debt and Liquidity - MGTX's debt-to-equity ratio is 27.19, indicating a relatively high level of debt compared to its equity [5][6]. - The current ratio is 0.88, suggesting potential liquidity concerns as it is below the standard threshold of 1 [5][6].

Core Viewpoint - Alvotech is expected to report a decline in earnings despite an increase in revenues for the quarter ending September 2025, with significant implications for its stock price based on the upcoming earnings report [2][6] Financial Performance Expectations - Wall Street estimates an earnings per share (EPS) of $0.05 and projected revenue of approximately $118.8 million for the upcoming quarterly earnings release on November 12, 2025 [1] - Analysts predict that if actual results exceed these estimates, the stock may rise, while a miss could lead to a decline in stock value [2] Management and Conference Call - Alvotech's management will hold a conference call on November 13 to discuss financial results and provide updates on pending approvals in the U.S. and Europe, which will be crucial for future earnings projections [3][6] Financial Metrics - The company has a price-to-earnings (P/E) ratio of approximately 24.77, indicating investor willingness to pay for earnings [4][6] - The price-to-sales ratio stands at about 3.10, reflecting the company's market value relative to its sales [4] - The enterprise value to sales ratio is around 5.10, providing insight into the company's valuation compared to its revenue [4] Cash Flow and Financial Structure - The enterprise value to operating cash flow ratio is negative at -67.10, suggesting potential challenges in cash flow generation [5] - The debt-to-equity ratio is notably negative at -7.32, indicating a unique financial structure or potential financial risk [5] - Despite these challenges, the current ratio is 1.82, suggesting the company can cover its short-term liabilities with its short-term assets [5][6]

Core Viewpoint - Cogent Biosciences, Inc. has announced the pricing of its public offerings, including 9,677,420 shares of common stock at $31.00 per share and $200 million in convertible senior notes, aiming to raise approximately $475.3 million in net proceeds for various corporate purposes [1][2][8]. Offering Details - The Equity Offering was upsized from an initial offering size of $200 million [1]. - The expected closing dates for the offerings are November 13, 2025, for the Equity Offering and November 18, 2025, for the Convertible Notes Offering [3]. - The Convertible Notes will have a 1.625% interest rate, maturing on November 15, 2031, with interest payable semi-annually starting May 15, 2026 [4]. Convertible Notes Features - Noteholders can convert their Convertible Notes under specific circumstances, with an initial conversion rate of 22.2469 shares per $1,000 principal amount, equating to a conversion price of approximately $44.95 per share, representing a 45% premium over the public offering price [5]. - The Convertible Notes are redeemable at Cogent's option starting November 20, 2029, under certain conditions [6]. - In the event of a "fundamental change," noteholders may require Cogent to repurchase their Convertible Notes at a cash price equal to the principal amount plus accrued interest [7]. Use of Proceeds - The net proceeds from the offerings will be allocated to repay $50 million of existing loans, development and regulatory activities for bezuclastinib and other product candidates, and general corporate purposes [8]. Company Overview - Cogent Biosciences focuses on developing precision therapies for genetically defined diseases, with its lead product, bezuclastinib, targeting the KIT D816V mutation associated with systemic mastocytosis and other cancers [12].

Core Viewpoint - Eledon Pharmaceuticals has initiated an underwritten public offering of its common stock and pre-funded warrants, with the intention to use the proceeds for clinical development and general corporate purposes [1][2]. Group 1: Offering Details - The offering includes common stock and pre-funded warrants, with a 30-day option for underwriters to purchase an additional 15% of the total shares sold [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or terms [1]. Group 2: Use of Proceeds - Eledon plans to utilize the net proceeds from the offering to support the clinical development of its product candidates and advance its pipeline programs, along with general corporate purposes [2]. Group 3: Company Background - Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing immune-modulating therapies for life-threatening conditions, with its lead product being tegoprubart, an anti-CD40L antibody [5]. - The company is conducting studies in areas such as kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS) [5].